SCHEMBL5539153

SCHEMBL5539153

CC(C)(C)OC(=O)N1CCN(CC(=O)N2CCC(=O)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.56
CHRM4 P08173 1/20 0.56
CHRM1 P11229 1/20 0.56
CHRM3 P20309 1/20 0.56
DTYMK P23919 2/20 0.50
DDB1 Q16531 1/20 0.49
CRBN Q96SW2 1/20 0.49
TERT O14746 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
USP2 O75604 1/20 0.43
PKM P14618 1/20 0.42
ESR2 Q92731 1/20 0.42
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20338357 0.85 CHRM2 (0.58) CHRM2CHRM4CHRM1CHRM3DTYMK
SCHEMBL27669441 0.84 USP2 (0.56) DDB1CRBNSMN1; SMN2USP2ESR2
SCHEMBL31028 0.84 USP2 (0.56) DDB1CRBNSMN1; SMN2USP2ESR2
SCHEMBL24029900 0.84 CHRM2 (0.56) CHRM2CHRM4CHRM1CHRM3DTYMK
SCHEMBL22181255 0.83 CYP11B2 (0.43) CHRM2CHRM4CHRM1CHRM3DTYMK
SCHEMBL15265090 0.83 GAA (0.56) CHRM2CHRM4CHRM1CHRM3DTYMK
Ammonia Solution, Strong SCHEMBL27841683 0.83 USP2 (0.55) DDB1CRBNSMN1; SMN2USP2ESR2
Ethylene Glycol SCHEMBL27346767 0.82 USP2 (0.50) CHRM2CHRM4CHRM1CHRM3DTYMK
Ethylene SCHEMBL3832936 0.81 USP2 (0.53) DTYMKDDB1CRBNSMN1; SMN2USP2
Iodomethane SCHEMBL15848230 0.81 USP2 (0.53) DDB1CRBNSMN1; SMN2USP2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020138398-A1 NOVEL COMPOUND INHIBITING LYSINE-SPECIFIC DEMETHYLATING ENZYME 1, METHOD FOR PRODUCING SAME, AND USE OF SAME 国立研究開発法人理化学研究所 2020-07-02 WO disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CHRM2 862/4885CHRM4 962/4885CHRM1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.